WO2022210784A1 - ヘテロシクリデンアセトアミド誘導体含有懸濁液 - Google Patents
ヘテロシクリデンアセトアミド誘導体含有懸濁液 Download PDFInfo
- Publication number
- WO2022210784A1 WO2022210784A1 PCT/JP2022/015691 JP2022015691W WO2022210784A1 WO 2022210784 A1 WO2022210784 A1 WO 2022210784A1 JP 2022015691 W JP2022015691 W JP 2022015691W WO 2022210784 A1 WO2022210784 A1 WO 2022210784A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aqueous suspension
- trifluoromethylchroman
- ylidene
- acetamide
- hydroxy
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title abstract description 27
- 150000003869 acetamides Chemical class 0.000 title 1
- 239000007900 aqueous suspension Substances 0.000 claims abstract description 288
- 150000003839 salts Chemical class 0.000 claims abstract description 172
- 239000012453 solvate Substances 0.000 claims abstract description 130
- MAWBBYZCTDJMDD-GXDHUFHOSA-N (2e)-n-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-2-[7-(trifluoromethyl)-2,3-dihydrochromen-4-ylidene]acetamide Chemical compound C\1COC2=CC(C(F)(F)F)=CC=C2C/1=C/C(=O)NC1=C(CC(O)CC2)C2=CC=C1 MAWBBYZCTDJMDD-GXDHUFHOSA-N 0.000 claims abstract description 112
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 97
- 229920000642 polymer Polymers 0.000 claims description 75
- -1 polyoxyethylene Polymers 0.000 claims description 61
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical group [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 60
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims description 39
- 229920000609 methyl cellulose Polymers 0.000 claims description 38
- 235000010981 methylcellulose Nutrition 0.000 claims description 38
- 239000001923 methylcellulose Substances 0.000 claims description 38
- 229920001664 tyloxapol Polymers 0.000 claims description 37
- 229960004224 tyloxapol Drugs 0.000 claims description 37
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 37
- 150000003751 zinc Chemical class 0.000 claims description 30
- 235000005074 zinc chloride Nutrition 0.000 claims description 30
- 239000011592 zinc chloride Substances 0.000 claims description 30
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical group [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 24
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 21
- 239000002202 Polyethylene glycol Substances 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 18
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 18
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 18
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 18
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 18
- 229920000053 polysorbate 80 Polymers 0.000 claims description 18
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 16
- 229940068968 polysorbate 80 Drugs 0.000 claims description 16
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 15
- 239000004359 castor oil Substances 0.000 claims description 15
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 14
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 14
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 14
- 235000019438 castor oil Nutrition 0.000 claims description 13
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 13
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 12
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 12
- 229960001763 zinc sulfate Drugs 0.000 claims description 12
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 9
- MAWBBYZCTDJMDD-HFQYIWAZSA-N FC(C1=CC=C2\C(\CCOC2=C1)=C\C(=O)NC1=CC=CC=2CC[C@H](CC1=2)O)(F)F Chemical group FC(C1=CC=C2\C(\CCOC2=C1)=C\C(=O)NC1=CC=CC=2CC[C@H](CC1=2)O)(F)F MAWBBYZCTDJMDD-HFQYIWAZSA-N 0.000 claims description 8
- 239000003889 eye drop Substances 0.000 abstract description 24
- 229940012356 eye drops Drugs 0.000 abstract description 14
- 239000003795 chemical substances by application Substances 0.000 abstract description 9
- 229920003174 cellulose-based polymer Polymers 0.000 abstract description 6
- 235000002639 sodium chloride Nutrition 0.000 description 183
- 238000000034 method Methods 0.000 description 73
- 239000002245 particle Substances 0.000 description 43
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 38
- 239000000203 mixture Substances 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 34
- 239000000872 buffer Substances 0.000 description 27
- 238000002156 mixing Methods 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 23
- 239000011701 zinc Substances 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 229910052725 zinc Inorganic materials 0.000 description 18
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 15
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- 239000013078 crystal Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 12
- 235000010338 boric acid Nutrition 0.000 description 12
- 229960002645 boric acid Drugs 0.000 description 12
- 229920002678 cellulose Polymers 0.000 description 12
- 239000001913 cellulose Substances 0.000 description 12
- 229920003023 plastic Polymers 0.000 description 12
- 239000004033 plastic Substances 0.000 description 12
- 239000004743 Polypropylene Substances 0.000 description 11
- 239000004327 boric acid Substances 0.000 description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 10
- 206010013774 Dry eye Diseases 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 8
- 102000003566 TRPV1 Human genes 0.000 description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 229910052783 alkali metal Inorganic materials 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000011975 tartaric acid Substances 0.000 description 8
- 235000002906 tartaric acid Nutrition 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 150000004677 hydrates Chemical class 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- 229920001155 polypropylene Polymers 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 101150016206 Trpv1 gene Proteins 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229920003169 water-soluble polymer Polymers 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 229910021538 borax Inorganic materials 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 235000010339 sodium tetraborate Nutrition 0.000 description 5
- 239000004328 sodium tetraborate Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229960000281 trometamol Drugs 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 159000000003 magnesium salts Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 159000000001 potassium salts Chemical class 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000002834 transmittance Methods 0.000 description 4
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 4
- BHHYHSUAOQUXJK-UHFFFAOYSA-L zinc fluoride Chemical compound F[Zn]F BHHYHSUAOQUXJK-UHFFFAOYSA-L 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101100256637 Drosophila melanogaster senju gene Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 2
- NBOCQTNZUPTTEI-UHFFFAOYSA-N 4-[4-(hydrazinesulfonyl)phenoxy]benzenesulfonohydrazide Chemical compound C1=CC(S(=O)(=O)NN)=CC=C1OC1=CC=C(S(=O)(=O)NN)C=C1 NBOCQTNZUPTTEI-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000202785 Calyptronoma Species 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920002675 Polyoxyl Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- ZSILVJLXKHGNPL-UHFFFAOYSA-L S(=S)(=O)([O-])[O-].[Ag+2] Chemical compound S(=S)(=O)([O-])[O-].[Ag+2] ZSILVJLXKHGNPL-UHFFFAOYSA-L 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 108010082714 Silver Proteins Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 2
- 108050004388 Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 2
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 2
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 2
- 229940071536 silver acetate Drugs 0.000 description 2
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 description 2
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 2
- 229910001958 silver carbonate Inorganic materials 0.000 description 2
- 229940071575 silver citrate Drugs 0.000 description 2
- XNGYKPINNDWGGF-UHFFFAOYSA-L silver oxalate Chemical compound [Ag+].[Ag+].[O-]C(=O)C([O-])=O XNGYKPINNDWGGF-UHFFFAOYSA-L 0.000 description 2
- 229910001923 silver oxide Inorganic materials 0.000 description 2
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 description 2
- 229940019931 silver phosphate Drugs 0.000 description 2
- 229910000161 silver phosphate Inorganic materials 0.000 description 2
- LMEWRZSPCQHBOB-UHFFFAOYSA-M silver;2-hydroxypropanoate Chemical compound [Ag+].CC(O)C([O-])=O LMEWRZSPCQHBOB-UHFFFAOYSA-M 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- QUTYHQJYVDNJJA-UHFFFAOYSA-K trisilver;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ag+].[Ag+].[Ag+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QUTYHQJYVDNJJA-UHFFFAOYSA-K 0.000 description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000004246 zinc acetate Substances 0.000 description 2
- 229960000314 zinc acetate Drugs 0.000 description 2
- 229940102001 zinc bromide Drugs 0.000 description 2
- 239000011667 zinc carbonate Substances 0.000 description 2
- 235000004416 zinc carbonate Nutrition 0.000 description 2
- 229910000010 zinc carbonate Inorganic materials 0.000 description 2
- 229940043825 zinc carbonate Drugs 0.000 description 2
- 239000011746 zinc citrate Substances 0.000 description 2
- 235000006076 zinc citrate Nutrition 0.000 description 2
- 229940068475 zinc citrate Drugs 0.000 description 2
- 239000011670 zinc gluconate Substances 0.000 description 2
- 235000011478 zinc gluconate Nutrition 0.000 description 2
- 229960000306 zinc gluconate Drugs 0.000 description 2
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 2
- 229940007718 zinc hydroxide Drugs 0.000 description 2
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 2
- 239000011576 zinc lactate Substances 0.000 description 2
- 235000000193 zinc lactate Nutrition 0.000 description 2
- 229940050168 zinc lactate Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 229960001296 zinc oxide Drugs 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 2
- 229910000165 zinc phosphate Inorganic materials 0.000 description 2
- 229940077935 zinc phosphate Drugs 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- RYPGDXXHPJZNKB-UHFFFAOYSA-N 2-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide Chemical compound OC1CCC=2C=CC=C(C2C1)CC(=O)N RYPGDXXHPJZNKB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- XDVOLDOITVSJGL-UHFFFAOYSA-N 3,7-dihydroxy-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound O1B(O)OB2OB(O)OB1O2 XDVOLDOITVSJGL-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MAWBBYZCTDJMDD-UHFFFAOYSA-N N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-2-[7-(trifluoromethyl)-2,3-dihydrochromen-4-ylidene]acetamide Chemical compound C1COC2=CC(C(F)(F)F)=CC=C2C1=CC(=O)NC1=C(CC(O)CC2)C2=CC=C1 MAWBBYZCTDJMDD-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000004388 gamma ray sterilization Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- XUBOMFCQGDBHNK-UHFFFAOYSA-N gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 XUBOMFCQGDBHNK-UHFFFAOYSA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229940113601 irrigation solution Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 1
- 229960005381 lifitegrast Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- VGTPKLINSHNZRD-UHFFFAOYSA-N oxoborinic acid Chemical compound OB=O VGTPKLINSHNZRD-UHFFFAOYSA-N 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229920005653 propylene-ethylene copolymer Polymers 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229950004535 rebamipide Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- This disclosure relates to fields such as medicine, healthcare, biology and biotechnology.
- the present disclosure relates, inter alia, to techniques for improving the redispersibility of suspensions containing heterocyclideneacetamide derivatives, and formulation techniques based thereon.
- the population of dry eye patients in Japan is at least about 8 million, and it is estimated that there are about 22 million people including potential patients who use over-the-counter eye drops without going to the hospital, and there are more than 1 billion people in the world.
- the use of televisions, computers, mobile terminals, etc. increases the number of times we stare at the screen and the number of times we blink decreases.
- the use of air conditioners, etc. dries the air, resulting in accelerated evaporation of tears. , is widely known to cause dry eye.
- refractive surgery and contact lens use result in dry eyes. Symptoms associated with dry eye include ocular discomfort, dryness, burning and irritation of the ocular surface.
- the present disclosure describes one heterocyclideneacetamide derivative, (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydro
- An aqueous suspension containing naphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof and having excellent redispersibility is provided.
- the present disclosure provides: (Item 1) (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable thereof an aqueous suspension comprising a salt or solvate, a cellulosic polymer, and a nonionic surfactant. (Item 2) The aqueous suspension according to the preceding items, wherein the concentration of the cellulosic polymer in the aqueous suspension is about 0.00007 w/v% to about 0.01 w/v%.
- aqueous suspension according to any one of the preceding items wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.01 w/v% to about 0.05 w/v%.
- the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil. Turbidity agent.
- aqueous suspension comprising a salt or solvate, a cellulosic polymer, and a nonionic surfactant, the concentration of the cellulosic polymer in the aqueous suspension is about 0.0001 w/v% to about 0.005 w/v%;
- the cellulosic polymer is at least one selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, the concentration of the nonionic surfactant in the aqueous suspension is from about 0.01 w/v% to about 0.05 w/v%; wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, and polyethylene glycol monostearate
- aqueous suspension comprising a salt or solvate, a cellulosic polymer, and a nonionic surfactant, the concentration of the cellulosic polymer in the aqueous suspension is about 0.0001 w/v% to about 0.005 w/v%;
- the cellulosic polymer is at least one selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, the concentration of the nonionic surfactant in the aqueous suspension is from about 0.01 w/v% to about 0.05 w/v%; wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, and polyethylene glycol monostearate
- aqueous suspension comprising a salt or solvate, a cellulosic polymer, and a nonionic surfactant, the concentration of the cellulosic polymer in the aqueous suspension is about 0.0001 w/v% to about 0.005 w/v%; the cellulosic polymer is methyl cellulose, the concentration of the nonionic surfactant in the aqueous suspension is from about 0.01 w/v% to about 0.05 w/v%; the nonionic surfactant is tyloxapol; Additionally containing zinc chloride, and borate buffer, the concentration of the zinc chloride in the aqueous suspension is from about 0.0005% w/v to about 0.01% w/v; the a salt or solvate, a cellulosic polymer, and a nonionic surfactant, the concentration of the cellulosic polymer in the aqueous suspension is about 0.0001 w/v% to about 0.005 w/v%;
- aqueous suspension comprising a salt or solvate, a cellulosic polymer, and a nonionic surfactant, the concentration of the cellulosic polymer in the aqueous suspension is about 0.0005 w/v% to about 0.003 w/v%; the cellulosic polymer is methyl cellulose, the concentration of the nonionic surfactant in the aqueous suspension is from about 0.01 w/v% to about 0.03 w/v%; the nonionic surfactant is tyloxapol; Additionally containing zinc chloride, and borate buffer, the concentration of the zinc chloride in the aqueous suspension is from about 0.001% w/v to about 0.005% w/v; the a salt or solvate, a cellulosic polymer, and a nonionic surfactant, the concentration of the cellulosic polymer in the aqueous suspension is about 0.0005 w/v% to about 0.003 w/v%;
- (Item B2) An aqueous suspension according to any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.0001 w/v% to about 0.5 w/v%.
- (Item B2a) The aqueous suspension according to any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.0001 w/v% to about 0.1 w/v%.
- (Item B3) An aqueous suspension according to any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.01 w/v% to about 0.05 w/v%.
- (Item B4) The aqueous suspension according to any one of the preceding items, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil. Turbidity agent.
- (Item B11) The aqueous suspension according to any one of the above items, wherein the cellulosic polymer is at least one selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose.
- (Item B12) The (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide is (E)-2 Any one of the preceding items which is -(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide Aqueous suspension agent according to item.
- (Item D2) The method according to the preceding items, wherein the concentration of the cellulosic polymer in the aqueous suspension is from about 0.00007 w/v% to about 0.01 w/v%.
- (Item D2a) The method according to the preceding items, wherein the concentration of the cellulosic polymer in the aqueous suspension is from about 0.00007 w/v% to about 0.007 w/v%.
- (Item D3) A method according to any one of the preceding items, wherein the concentration of the cellulosic polymer in the aqueous suspension is from about 0.0001 w/v % to about 0.008 w/v %.
- (Item D3a) A method according to any one of the preceding items, wherein the concentration of the cellulosic polymer in the aqueous suspension is from about 0.0001 w/v % to about 0.005 w/v %.
- (Item D4) The method according to any one of the above items, wherein the cellulosic polymer is at least one selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose.
- (Item D5) A method according to any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.0001% w/v to about 0.5% w/v.
- (Item D6) A method according to any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.0001% w/v to about 0.1% w/v.
- (Item D6a) A method according to any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.01 w/v % to about 0.05 w/v %.
- the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil.
- (Item D10) A method according to any one of the preceding items, wherein the concentration of the zinc or silver salt in the aqueous suspension is from about 0.0001 w/v % to about 0.05 w/v %.
- (Item D11) A method according to any one of the preceding items, wherein the zinc salt is zinc chloride or zinc sulfate.
- (Item D11a) A method according to any one of the preceding items, wherein the silver salt is silver nitrate.
- (Item G1) (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable thereof
- a method for improving the stability of an aqueous suspension comprising a salt or solvate comprising: (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable thereof mixing a salt or solvate of tyloxapol with tyloxapol to prepare an aqueous suspension.
- an aqueous suspension having excellent redispersibility can be provided.
- the present disclosure suppresses the phenomenon that the suspended particles are not uniformly dispersed, enables stable administration of the required amount of the active ingredient, and stably and sufficiently exerts the pharmacological effect. Realize to do. It contributes to improvement of patient adherence and convenience.
- FIG. 1 is a graph showing the transmittance of each bottle (colorless PE, colorless PP, brown PE) at each wavelength.
- aqueous suspension is used in the same sense as the term used in this field, and is a liquid agent containing at least a portion of water, in which the components to be mixed are suspended. It is a state in which solid particles are present in a liquid.
- pharmaceutically acceptable salts refer to relatively non-toxic, inorganic or organic acid addition salts or inorganic or organic base addition salts of the compounds of the present disclosure.
- solvate refers to a compound of the present disclosure or a pharmaceutically acceptable salt thereof and any solvent that forms a single group by interaction, for example, with an organic solvent Solvates (for example, alcohol (ethanol etc.) hydrates), hydrates and the like are included. When forming a hydrate, it may be coordinated with any number of water molecules. Examples of hydrates include monohydrates and dihydrates.
- the term “redispersibility” refers to the fact that a liquid containing particles such as a suspension (in the case of a suspension, it is also referred to as “suspended particles”) is stored for a certain period of time so that the solvent of the liquid It refers to the easiness of dispersion when the particles that have sedimented therein are uniformly redispersed throughout the liquid.
- "redispersibility” is evaluated by a test using a shaking operation or an inversion operation.
- the term “shaking operation” refers to the action of holding a container filled with an “aqueous suspension” and shaking it up and down.
- the container In the “shaking operation", the container is shaken vertically 10 to 15 cm wide, and shaken once until it returns to the original position after being shaken up.
- the redispersibility test by "shaking operation” is performed with 3 to 5 samples per formulation, the average number of sets is calculated from the number of sets required for redispersion of each sample, and the number of times converted to the number of shakings is used.
- turning operation refers to the action of holding a container filled with an “aqueous suspension” and turning it upside down.
- the redispersibility test by “inversion operation” is performed with 3 to 5 samples per formulation, and the container is inverted 180 ° up and down at a speed of 1 second / time, and then inverted 180 ° again to make it upright. The operation is set to one overturn.
- the term "improved redispersibility” means that particles that have sedimented in a liquid containing particles such as a suspension are easily dispersed again. It can be said that the redispersibility was improved when the number of times of "shaking operation” or "overturning operation” decreased.
- Stability refers to (E)-2-(7-trifluoromethylchroman-4-ylidene) dissolved and/or suspended in an aqueous suspension by storage for a certain period of time.
- “stability” as used herein means (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6 ,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, of (E)-2- in an aqueous suspension stored for a period of time after preparation (7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.
- the content maintenance rate which is the ratio of the content of, is typically evaluated by dissolving (E)-2-(7-trifluoromethylchroman-4-ylidene) in an aqueous suspension.
- improved stability means that the stability is improved when the content maintenance rate is high in comparison of arbitrary formulations.
- the "average particle size of suspended particles” means (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8- Refers to the median particle size (D 50 ) of the particles of tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, measured using a laser diffraction particle size distribution analyzer. is the value to be
- cellulose-based polymer is a type of water-soluble polymer, and refers to a cellulose derivative in which the hydroxyl groups of cellulose are partially converted to other substituents.
- cellulosic polymers include methyl cellulose (hereinafter sometimes referred to as "MC”), hydroxypropylmethyl cellulose, carboxymethyl cellulose (hereinafter sometimes referred to as "CMC”), ethyl cellulose, propyl cellulose, hydroxy Examples include methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and sulfonated cellulose derivatives.
- nonionic surfactant is also referred to as a nonionic surfactant, and refers to a surfactant in which the portion of the hydrophilic group is nonionic. Whether or not it is a nonionic surfactant can be easily determined by those skilled in the art by confirming that it does not ionize (does not exhibit ionicity) when dissolved in water.
- nonionic surfactants include tyloxapol, polyoxyl stearates (polyethylene glycol monostearate, polyethylene glycol monostearate 40 (MYS-40), polyethylene glycol monostearate 400, etc.), polyoxyethylene sorbitan fatty acid esters.
- polyoxyethylene sorbitan monooleate polysorbate 80
- polyoxyethylene sorbitan tristearate polyoxyethylene sorbitan tristearate
- polyoxy Ethylene hydrogenated castor oils polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60 (HCO-60), etc.
- zinc salt refers to a salt containing zinc ion (Zn 2+ ) as a constituent ion (a compound of zinc and an organic acid or an inorganic acid) or an oxide of zinc.
- zinc halides such as zinc chloride, zinc bromide or zinc fluoride, zinc sulfate, zinc acetate, zinc phosphate, zinc carbonate, zinc hydroxide, zinc citrate, zinc lactate, zinc gluconate, zinc oxide, or and hydrates thereof.
- silver salt refers to a salt containing silver ions (Ag + ) as constituent ions (a compound of silver and an organic acid or an inorganic acid) or an oxide of silver. Examples include silver nitrate, silver bromide, silver oxide, silver acetate, silver carbonate, silver citrate, silver lactate, silver phosphate, silver oxalate, silver thiosulfate, silver protein, and hydrates thereof.
- Aqueous suspensions comprising a pharmaceutically acceptable salt or solvate and a nonionic surfactant may be provided.
- aqueous suspension comprising a pharmaceutically acceptable salt or solvate, a cellulosic polymer, and a nonionic surfactant.
- aqueous suspension comprising a pharmaceutically acceptable salt or solvate, a nonionic surfactant, and a zinc or silver salt.
- aqueous suspension comprising a pharmaceutically acceptable salt or solvate, a cellulosic polymer, a nonionic surfactant, and a zinc or silver salt.
- a method may be provided comprising the step of preparing a liquid formulation.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or A method for improving the redispersibility of suspended particles of a pharmaceutically acceptable salt or solvate thereof comprising: (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-( 7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, a cellulosic polymer, and a nonionic surfactant mixed to prepare an aqueous suspension.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or A method for improving the redispersibility of suspended particles of a pharmaceutically acceptable salt or solvate thereof comprising: (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-( 7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, a nonionic surfactant, and a zinc salt or silver salt
- a method may be provided comprising mixing to form an aqueous suspension.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or A method for improving the redispersibility of suspended particles of a pharmaceutically acceptable salt or solvate thereof comprising: (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-( 7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, a cellulosic polymer, a nonionic surfactant, and zinc
- a method may be provided comprising the step of mixing with a salt or silver salt to prepare an aqueous suspension.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) A method for improving the redispersibility of an aqueous suspension containing acetamide, or a pharmaceutically acceptable salt or solvate thereof, comprising (E)-2-(7-trifluoromethylchroman-4-ylidene )-N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, containing a cellulose-based high A method may be provided comprising adding a molecule.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) A method for improving the redispersibility of an aqueous suspension containing acetamide, or a pharmaceutically acceptable salt or solvate thereof, comprising (E)-2-(7-trifluoromethylchroman-4-ylidene )-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, to an aqueous suspension containing a nonionic interface
- a method may be provided comprising adding an active agent.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) A method for improving the redispersibility of an aqueous suspension containing acetamide, or a pharmaceutically acceptable salt or solvate thereof, comprising (E)-2-(7-trifluoromethylchroman-4-ylidene )-N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, containing a cellulose-based high
- a method may be provided comprising adding a molecule and a non-ionic surfactant.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) A method for improving the redispersibility of an aqueous suspension containing acetamide, or a pharmaceutically acceptable salt or solvate thereof, comprising (E)-2-(7-trifluoromethylchroman-4-ylidene )-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, to an aqueous suspension containing a nonionic interface
- a method may be provided comprising adding an active agent and a zinc or silver salt.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) A method for improving the redispersibility of an aqueous suspension containing acetamide, or a pharmaceutically acceptable salt or solvate thereof, comprising (E)-2-(7-trifluoromethylchroman-4-ylidene )-N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, containing a cellulose-based high
- a method may be provided comprising adding a molecule and a zinc or silver salt.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) A method for improving the redispersibility of an aqueous suspension containing acetamide, or a pharmaceutically acceptable salt or solvate thereof, comprising (E)-2-(7-trifluoromethylchroman-4-ylidene )-N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, containing a cellulose-based high
- a method may be provided comprising adding a molecule, a nonionic surfactant, and a zinc or silver salt.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide includes the R-form (CAS. No.920332-28-1), S form (CAS.No.920332-29-2), or racemic form (CAS.No.920332-27-0), but more preferably R form (( E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (compound in the present disclosure Also referred to as (1))).
- a pharmaceutically acceptable salt of the compound of the present disclosure is not particularly limited as long as it is a pharmaceutically acceptable salt.
- Specific examples include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, Mineral acids such as nitric acid and phosphoric acid; aliphatic monocarboxylic acids such as formic acid, acetic acid, propionic acid, butyric acid, valeric acid, enanthic acid, capric acid, myristic acid, palmitic acid, stearic acid, lactic acid, sorbic acid and mandelic acid , benzoic acid, salicylic acid and other aromatic monocarboxylic acids, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, malic acid, tartaric acid and other aliphatic dicarboxylic acids, and citric acid and other aliphatic tricarboxylic acids.
- Carboxylic acids such as aliphatic sulfonic acids such as methanesulfonic acid, ethanesulfonic acid and 2-hydroxyethanesulfonic acid, and aromatic sulfonic acids such as benzenesulfonic acid and p-toluenesulfonic acid.
- organic sulfonic acids such as aliphatic sulfonic acids such as methanesulfonic acid, ethanesulfonic acid and 2-hydroxyethanesulfonic acid
- aromatic sulfonic acids such as benzenesulfonic acid and p-toluenesulfonic acid.
- inorganic base addition salts with metals such as alkali metals or alkaline earth metals such as sodium, potassium, magnesium, and calcium
- organic base addition salts such as methylamine, ethylamine, ethanolamine, pyridine, lysine, arginine, ornithine, etc. is mentioned
- salts can be obtained by a conventional method, for example, by mixing an equivalent amount of the compound of the present disclosure with a solution containing the desired acid or base and collecting the desired salt by filtration or distilling off the solvent. sell.
- Compounds of the present disclosure or salts thereof may also form solvates with water or solvents such as ethanol.
- TRPV1 transient receptor potential vanilloid 1
- VR1 transient receptor potential vanilloid 1
- TRPV1 is a TRP channel that was cloned from the dorsal root ganglion (DRG) as a cation channel that responds to capsaicin. Chemistry Vol. 85, No. 7: 561-565). TRPV1 is known to increase its activity during inflammation or tissue damage and induce hyperalgesia. Therefore, TRPV1 is of interest as a potential drug target for pain therapy.
- DRG dorsal root ganglion
- TRPV1 antagonists are effective against various pain models such as inflammatory pain, neuropathic pain and osteoarthritis (Seikagaku Vol. 85, No. 7: 561- 565).
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide By mixing a pharmaceutically acceptable salt or solvate with a cellulosic polymer and a nonionic surfactant to form an aqueous suspension, (E)-2-(7-trifluoromethylchroman -4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, improves redispersibility be able to.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide , or a pharmaceutically acceptable salt or solvate thereof, for improving the redispersibility of an aqueous suspension, the composition comprising a nonionic surfactant. can do.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide , or a pharmaceutically acceptable salt or solvate thereof, for improving the redispersibility of an aqueous suspension the composition providing a composition comprising a cellulosic polymer be able to.
- composition comprising a cellulosic polymer and a nonionic surfactant
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide , or a pharmaceutically acceptable salt or solvate thereof, comprising a cellulosic polymer and a zinc or silver salt for improving the redispersibility of an aqueous suspension of A composition comprising:
- a composition comprising a salt can be provided.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide , or a pharmaceutically acceptable salt or solvate thereof, in the aqueous suspensions of the present disclosure is generally about 0.01% w/v to about 5% w/v, preferably about 0.1% w/v v% to about 3% w/v%, more preferably about 0.2% w/v% to about 2% w/v%, particularly preferably about 0.2% w/v% to about 1.5% It can be present at a concentration of w/v %, more preferably from about 0.3% w/v % to about 1.0% w/v %.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide , or a pharmaceutically acceptable salt or solvate thereof, in the aqueous suspension of the present disclosure usually about 0.01 w/v% to about 5 w/v%, preferably about 0 .1% w/v% to about 3% w/v%, more preferably about 0.2% w/v% to about 2% w/v%, particularly preferably about 0.2% w/v% to It can be present at a concentration of about 1.5% w/v%, more preferably from about 0.3% w/v% to about 1.0% w/v%.
- the cellulosic polymer is not particularly limited as long as it is pharmaceutically acceptable, but methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, ethylcellulose, propylcellulose, hydroxymethylcellulose , hydroxyethyl cellulose, hydroxypropyl cellulose, sulfonated cellulose derivatives, or pharmaceutically acceptable salts thereof, and the like. Moreover, these cellulose-based polymer compounds may be used singly or in combination of two or more. Cellulosic polymers are preferably methylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose from the viewpoint of redispersibility of aqueous suspensions.
- Cellulose-based polymers are linear water-soluble polymers with glucose as the basic unit.
- a cellulosic polymer is added to an aqueous suspension containing compound (1), the cellulosic polymer is appropriately distributed around the suspended particles in the presence of the nonionic surfactant.
- cellulose-based polymers form a sheet structure between cellulose particles. maintains an appropriate distance and contributes to the formation of a bulky sedimentation layer.
- the cellulosic polymer acts as an appropriate steric hindrance by adjusting the cellulosic polymer to an arbitrary concentration relative to the suspended particles.
- aqueous suspension that forms a bulky sedimentation layer and has good redispersibility can be prepared. Therefore, in one embodiment of the present disclosure, the use of a cellulosic polymer can be expected to prepare an aqueous suspension having excellent redispersibility.
- carboxyvinyl polymer and polyvinylpyrrolidone have acrylic acid and N-vinyl-2-pyrrolidone main chain structures, respectively, and are water-soluble polymers that do not have a three-dimensional structure like a sheet structure.
- these water-soluble polymers are distributed around suspended particles, the effect of maintaining the distance between suspended particles is considered to be weaker than that of cellulosic polymers.
- the methyl cellulose used is not particularly limited, but any methyl cellulose having different methoxy group substitution rates, molecular weights, viscosities, etc. may be used, and these may be used alone or Two or more kinds can be used in combination.
- the degree of substitution of methoxy groups in methylcellulose is usually in the range of about 20 to about 40%, preferably in the range of 26 to 33%.
- the viscosity of methyl cellulose (20 ° C., 2 wt% aqueous solution) is usually 1 to 10000 mPa s, preferably 3 to 3000 mPa s, more preferably 4 to 1500 mPa s, particularly preferably 3 to 50 mPa.
- ⁇ s more preferably 10 to 20 mPa ⁇ s.
- Examples of commercially available products include METOLOSE SM-4, METOLOSE SM-15, METOLOSE SM-25, SM-100, SM-400, METOLOSE SM-1500, SM-4000 (Shin-Etsu Chemical Co., Ltd.) and the like.
- the cellulosic polymer is generally about 0.00007 w/v% to about 0.01 w/v%, preferably about 0.0001 w/v%, in the aqueous suspension of the present disclosure. to about 0.008 w/v%, more preferably about 0.0005 w/v% to about 0.005 w/v%, particularly preferably about 0.0006 w/v% to about 0.003 w/v%, more preferably It can be present at a concentration of about 0.0007 w/v % to about 0.002 w/v %, most preferably about 0.0008 w/v % to about 0.001 w/v %.
- the cellulosic polymer is typically about 0.00007 w/v% to about 0.007 w/v%, preferably about 0.0001 w/v, in the aqueous suspension of the present disclosure. % to about 0.005 w/v%, more preferably about 0.0003 w/v% to about 0.004 w/v%, particularly preferably about 0.0005 w/v% to about 0.003 w/v%, even more preferably can be present at a concentration of about 0.0007 w/v % to about 0.001 w/v %, most preferably about 0.001 w/v %.
- methyl cellulose when used as the cellulosic polymer, it is generally about 0.00007 w/v % to about 0.007 w/v %, preferably about 0.007 w/v %, in the aqueous suspension of the present disclosure.
- the nonionic surfactant is not particularly limited as long as it is pharmaceutically acceptable.
- Tyloxapol polyoxyls stearate (polyethylene glycol monostearate, monostearate polyethylene glycol 40 (MYS-40), polyethylene glycol monostearate 400, etc.), polyoxyethylene sorbitan fatty acid esters (polyoxyethylene sorbitan monooleate (polysorbate 80), polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan tristearate, etc.), polyoxyethylene hydrogenated castor oils (polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60 (HCO-60), etc.).
- Nonionic surfactants may be used singly or in combination of two or more.
- Nonionic surfactants are preferably tyloxapol, polysorbate 80, polyethylene glycol monostearate, polyoxyethylene hydrogenated castor oil 60, tyloxapol, polysorbate 80, monostearin from the viewpoint of redispersibility or stability of aqueous suspensions. Acid polyethylene glycol is more preferred, and tyloxapol is even more preferred.
- the nonionic surfactant is from about 0.0001 w/v% to about 0.5 w/v%, preferably about 0.0001 w/v%, in the aqueous suspension of the present disclosure. It can be present at a concentration of from to about 0.1 w/v %, more preferably from about 0.01 w/v % to about 0.005 w/v %.
- the nonionic surfactant is from about 0.0001 w/v % to about 0.5 w/v %, preferably about 0.005 w/v, in the aqueous suspensions of the present disclosure. % to about 0.1 w/v %, more preferably about 0.01 w/v % to about 0.05 w/v %, particularly preferably about 0.01 w/v % to about 0.03 w/v % can exist.
- the amount in the aqueous suspension of the present disclosure is from about 0.0001 w/v % to about 0.5 w/v %, preferably about 0.5 w/v %. 005 w/v% to about 0.1 w/v%, more preferably about 0.01 w/v% to about 0.05 w/v%, particularly preferably about 0.01 w/v% to about 0.03 w/v% can be present in concentrations of
- zinc halides such as zinc chloride, zinc bromide or zinc fluoride, zinc sulfate, zinc acetate, zinc phosphate, zinc carbonate, zinc hydroxide, zinc citrate, zinc lactate, zinc gluconate, zinc oxide, or hydrates thereof;
- the zinc salt is present in the aqueous suspension of the present disclosure from about 0.0001 w/v% to about 0.05 w/v%, more preferably from about 0.0005 w/v% to about It can be present in a concentration of 0.01 w/v %, particularly preferably from about 0.001 w/v % to about 0.005 w/v %.
- w/v % when zinc chloride is used as the zinc salt, about 0.0001 w/v % to about 0.05 w/v %, more preferably about 0.0005 w/v %, is used in the aqueous suspension of the present disclosure. /v % to about 0.01 w/v %, particularly preferably from about 0.001 w/v % to about 0.005 w/v %.
- silver salts that can be added to the aqueous suspension of the present disclosure include silver nitrate, silver bromide, silver oxide, silver acetate, silver carbonate, silver citrate, silver lactate, and silver phosphate. , silver oxalate, silver thiosulfate, silver protein, or hydrates thereof.
- the silver salt is present in the aqueous suspension of the present disclosure from about 0.0001 w/v% to about 0.05 w/v%, more preferably from about 0.0005 w/v% to about It can be present in a concentration of 0.01 w/v %, particularly preferably from about 0.001 w/v % to about 0.005 w/v %.
- the number of times of shaking required for redispersion described above is usually about 15 times or less, preferably about 13 times or less, more preferably about 12 times or less, particularly preferably about 11 times or less, further preferably about 10 times. It can be judged that the redispersibility is improved when the following conditions are satisfied.
- the measurement by falling operation reproduces the evaluation when used by patients who have weak hand strength due to some disorder or symptom and who have difficulty redispersing by shaking. It can be said that the redispersibility at the time of use is evaluated.
- the number of tumbling operations required for redispersion described above is usually about 40 times or less, preferably about 35 times or less, more preferably about 30 times or less, particularly preferably about 25 times or less, further preferably about 20 times. It can be judged that the redispersibility is improved when the number is less than or equal to the number of times.
- redispersibility can be assessed by any means, for example, by filling a container with an aqueous suspension of the present disclosure and subjecting the container to It can also be evaluated by counting the number of times until the suspended particles are redispersed by shaking or turning.
- the average particle size (D 50 ) of 1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof is not particularly limited, but is usually about 0.1 ⁇ m to about 50 ⁇ m, preferably about 0.1 ⁇ m to about 50 ⁇ m. .5 ⁇ m to about 10 ⁇ m, particularly preferably about 1 ⁇ m to about 10 ⁇ m, more preferably about 1 ⁇ m to about 5 ⁇ m.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalene in the aqueous suspension of the disclosure -1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof can be used as a crystal form, and the crystal form is not particularly limited as long as it does not affect redispersibility.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R )-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide type I crystals, type II crystals, type III crystals or mixtures thereof can be used.
- the type I crystal is preferably used.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide , or a pharmaceutically acceptable salt or solvate thereof can be suspended in an aqueous solution containing tyloxapol to form (E)-2-(7-trifluoromethylchroman-4-ylidene)-N in aqueous solution.
- a composition for improving the stability of tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, said composition comprising tyloxapol. be able to.
- (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalene-1 in an aqueous suspension -yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof comprising: (E)-2-(7-trifluoromethylchroman-4-ylidene)-N- (7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, and tyloxapol are mixed to prepare an aqueous suspension
- a method is provided that includes steps.
- the stability is determined by storing (E)-2-(7-trifluoromethylchroman-4-ylidene) dissolved and/or suspended in an aqueous suspension over a period of time.
- -N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or its pharmaceutically acceptable salt or solvate content retention rate (residual rate) can be evaluated.
- the aqueous suspension is an ophthalmic suspension and can be provided as an eye injection, eye drops or eye irrigation solution.
- ophthalmic suspensions can be provided in the form of suspensions or solutions in which the active ingredient is suspended in an aqueous solvent (eg, phosphate-buffered saline).
- the aqueous suspension can be eye drops for treating dry eye.
- Dry eye is a disease accompanied by subjective symptoms such as eye discomfort, and requires long-term and regular treatment.
- dry eye therapeutic drugs are generally administered in a large number of doses, there is a strong demand for formulations with good patient adherence and convenience.
- suspension with poor redispersibility there is concern that the suspended particles will not be uniformly dispersed, the desired active ingredient will not be administered, and the pharmacological effect will not be sufficiently exhibited. From these points of view as well, redispersibility is a major issue in eye drops for treating dry eye, and the provision of an aqueous suspension having excellent redispersibility according to the present disclosure is highly valuable.
- aqueous suspensions of the present disclosure can be administered by any suitable route determined by those of ordinary skill in the art, including but not limited to ocular injection, topical application (including application to the eye), It can be formulated to be suitable for administration by an administration route selected from eye drop, intravenous injection, drip, oral, parenteral, transdermal and the like.
- Aqueous suspensions of the present disclosure may contain any pharmaceutically acceptable additives and/or excipients known in the art.
- Additives include, but are not limited to, stabilizers, pH adjusters, buffers, and preservatives (preservatives).
- the stabilizer is not particularly limited as long as it is pharmaceutically acceptable, and examples include polyvinylpyrrolidone, monoethanolamine, cyclodextrin, dextran, ascorbic acid, tocopherol, dibutylhydroxytoluene, sulfites, and the like. , the content is preferably about 0.001 w/v% to about 1 w/v% of the total amount of the composition.
- the pH adjuster is not particularly limited as long as it is pharmaceutically acceptable.
- examples include acids such as hydrochloric acid, acetic acid, boric acid, aminoethylsulfonic acid, epsilon-aminocaproic acid; sodium hydroxide, potassium hydroxide. , borax, triethanolamine, monoethanolamine, sodium hydrogen carbonate, alkalis such as sodium carbonate, etc., and the content thereof is, for example, 0 to about 20 w/v% with respect to the total amount of the aqueous suspension agent. .
- the aqueous suspension of the present disclosure is adjusted to a pH of generally about 4 to about 8, preferably about 5.0 to about 8, by mixing a pH adjuster as described above, if necessary. 8.0, more preferably about 6.0 to about 8.0, particularly preferably about 7.0 to about 8.0, and even more preferably about 7.2 to about 7.8.
- the buffering agent used in the aqueous suspension of the present disclosure is not particularly limited as long as it is pharmaceutically acceptable.
- borate buffer, phosphate buffer, Tris buffer, citrate buffer , tartaric acid buffers, acetic acid buffers, amino acid buffers, etc. but from the viewpoint of redispersibility or stability of the aqueous suspension, boric acid buffers or phosphate buffers are preferred, and boric acid buffers agents are particularly preferred.
- the concentration of the buffering agent may be appropriately set within a range in which the desired buffering capacity can be imparted to the aqueous solution. is preferably about 1 w/v% to about 5 w/v%, more preferably about 1 w/v% to about 3 w/v%.
- the borate buffer is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include boric acid and/or salts thereof.
- Boric acid is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include orthoboric acid, metaboric acid, tetraboric acid and the like.
- the salt of boric acid is not particularly limited as long as it is pharmaceutically acceptable.
- Metal salts such as sodium salt, potassium salt, calcium salt, magnesium salt, aluminum salt; triethylamine, triethanolamine , morpholine, piperazine, pyrrolidine and other organic amine salts. Boric acid or a salt thereof may be used singly or in combination of two or more.
- a preferred embodiment of the borate buffer is a combination of boric acid and borax.
- the ratio of boric acid and borax is not particularly limited. , more preferably 30 to 100 parts by mass, and particularly preferably 40 to 60 parts by mass.
- phosphate buffers include phosphoric acid and/or salts thereof.
- the salt of phosphoric acid is not particularly limited as long as it is pharmaceutically acceptable.
- dialkali metal salts of hydrogen phosphate such as disodium hydrogen phosphate and dipotassium hydrogen phosphate
- alkali metal dihydrogen phosphate such as potassium dihydrogen phosphate
- tri-alkali metal phosphate such as tri-sodium phosphate and tripotassium phosphate.
- the salt of phosphoric acid may be in the form of a solvate such as a hydrate.
- disodium hydrogen phosphate the form of dodecahydrate, In some cases, it may be in the form of a dihydrate or the like.
- the phosphate buffer one of phosphoric acid and salts thereof may be selected and used alone, or two or more thereof may be used in combination.
- phosphoric acid and salts thereof phosphates are preferred, more preferably at least one of dialkali metal hydrogen phosphate and alkali metal dihydrogen phosphate, particularly preferably disodium hydrogen phosphate and dihydrogen phosphate At least one of sodium is included.
- Tris buffers include Tris (also known as trishydroxymethylaminomethane) and/or salts thereof.
- the tris salt is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include salts such as acetate, hydrochloride, maleate and sulfonate.
- the Tris acid buffer one selected from Tris and salts thereof may be used alone, or two or more thereof may be used in combination.
- the Tris buffer specifically includes trometamol and/or salts thereof.
- the salt of trometamol is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include organic acid salts such as acetate; inorganic acid salts such as hydrochloride and sulfonate.
- the tris acid buffer one selected from trometamol and salts thereof may be used alone, or two or more thereof may be used in combination. Among trometamol and salts thereof, trometamol is preferred.
- Citric acid buffers specifically include citric acid and/or salts thereof.
- the salt of citric acid is not particularly limited as long as it is pharmaceutically acceptable. Examples include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; be done.
- the citric acid salt may be in the form of a solvate such as a hydrate.
- the citric acid buffer one of citric acid and salts thereof may be selected and used alone, or two or more thereof may be used in combination. Among citric acid and salts thereof, citric acid salts are preferred, alkali metal citric acid salts are more preferred, and sodium citrate is particularly preferred.
- tartaric acid buffers include tartaric acid and/or salts thereof.
- Salts of tartaric acid are not particularly limited as long as they are pharmaceutically acceptable, and examples thereof include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; .
- the salt of tartaric acid may be in the form of a solvate such as a hydrate.
- the tartaric acid buffer one of tartaric acid and salts thereof may be selected and used alone, or two or more thereof may be used in combination.
- acetate buffers include acetic acid and/or salts thereof.
- the salt of acetic acid is not particularly limited as long as it is pharmaceutically acceptable. Examples include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; ammonium salts, etc. are mentioned.
- the acetic acid salt may be in the form of a solvate such as a hydrate.
- the acetate buffer one of acetic acid and salts thereof may be selected and used alone, or two or more thereof may be used in combination.
- amino acid buffers include acidic amino acids and/or salts thereof.
- acidic amino acids include aspartic acid and glutamic acid.
- Salts of acidic amino acids are not particularly limited as long as they are pharmaceutically acceptable, and examples thereof include alkali metal salts such as sodium salts and potassium salts.
- the amino acid buffer one selected from acidic amino acids and salts thereof may be used alone, or two or more thereof may be used in combination.
- Preservatives are not particularly limited as long as they are pharmaceutically acceptable. Examples include sorbic acid, potassium sorbate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, and butyl parahydroxybenzoate. paraoxybenzoic acid ester, chlorhexidine gluconate, benzalkonium chloride, benzethonium chloride, quaternary ammonium salts such as cetylpyridinium chloride, alkylpolyaminoethylglycine, chlorobutanol, polyquad, polyhexamethylenebiguanide, chlorhexidine, etc. The content thereof can be appropriately changed depending on the type thereof, and is, for example, about 0.0001 w/v% to about 0.2 w/v% of the total amount of the aqueous suspension.
- aqueous solvent such as sterilized purified water, physiological saline, a buffer (e.g., phosphate buffer, citrate buffer, acetate buffer, etc.), or cottonseed oil. , soybean oil, sesame oil, peanut oil, and other vegetable oils.
- a buffer e.g., phosphate buffer, citrate buffer, acetate buffer, etc.
- cottonseed oil e.g., soybean oil, sesame oil, peanut oil, and other vegetable oils.
- the container for containing the aqueous suspension of the present disclosure is not particularly limited, and examples thereof include glass containers and plastic containers.
- the plastic container may be made of any material such as polyester (polyethylene terephthalate, polyarylate), polycarbonate, polyethylene or polypropylene, mixtures thereof, and mixtures thereof.
- the containers used in the present disclosure may be those used in the medical field or otherwise. In one embodiment, it can be made of any material that can meet the "standard for plastic containers for eye drops" in Japan or other equivalent standards.
- the shape of the container used may be arbitrary, and any shape can be used as long as it is a shape for eye drops.
- the aqueous suspension of the present disclosure can be filled into any eye drop container commonly used in the medical field, such as polyethylene (preferably low density polyethylene) or polypropylene, preferably colorless polypropylene container. can do.
- polyethylene preferably low density polyethylene
- polypropylene preferably colorless polypropylene container. can do.
- Table 1 shows the test results .
- the number of times of shaking was 15 times or less.
- the number of times of shaking was the least, 8.3 times.
- the surface tension of a separately prepared base (formulation excluding compound (1) and tyloxapol) was 54.6 mN/m, and there was no correlation between redispersibility and surface tension.
- Test Example 2 Comparative study of cellulose derivatives
- HPMC Hydroxypropyl methylcellulose
- CMC carboxymethyl cellulose
- 60SH-4000 was used as hydroxypropylmethylcellulose
- Celogen PR-S was used as carboxymethylcellulose.
- the above type I crystal was used.
- Table 2 shows the test results .
- Test Example 3 Comparative study of nonionic surfactants
- a suspension having the composition shown in Table 3 was prepared, and the number of times of shaking required for redispersion was determined in the same manner as in Test Example 1.
- Polysorbate 80 was manufactured by NOF, and polyethylene glycol monostearate 40 (MYS-40) was manufactured by Nippon Surfactant Kogyo.
- MYS-40 polyethylene glycol monostearate 40
- Table 3 shows the test results . Suspensions containing tyloxapol, polysorbate 80 and MYS-40 were shaken 15 times or less.
- Test Example 4 Comparative examination of water-soluble polymers other than cellulose
- a suspension having the composition shown in Table 4 was prepared, and the number of times of shaking required for redispersion was obtained in the same manner as in Test Example 1.
- Polyvinylpyrrolidone (PVP) from BASF Japan, xanthan gum from DSP Gokyo Food & Chemical, and carboxyvinyl polymer (CVP) from Lubrizol were used.
- Kollidon 30 was used as polyvinylpyrrolidone
- 974P was used as carboxyvinyl polymer.
- the above type I crystal was used.
- Table 4 shows the test results .
- the suspension containing PVP, xanthan gum, and CVP was shaken 15 times or more.
- Table 5 shows the test results .
- the number of inversion operations increased from 47.3 to 24.7.
- zinc chloride was added to Formula 28, the number of tipping operations was 32.3.
- the number of inversion operations was 16.0.
- the aqueous solution was stored at 25° C. for 1 month (1M), and the content of compound (1) in the solution was measured using a liquid chromatography device (manufactured by Shimadzu Corporation) under the following conditions.
- the content retention rate was determined as the ratio (%) of the measured content after storage to the amount of compound (1) used for preparation.
- Table 6 shows the measurement results .
- the content retention rate of compound (1) after 1M storage at 25° C. was 100%, and compound (1) was stable in an aqueous solution containing tyloxapol.
- Test Example 7 Change in redispersibility due to addition of each metal
- Suspensions having the compositions shown in Tables 7 to 9 were prepared, and the number of inversion operations required for redispersion was determined in the same manner as in Test Example 5.
- Zinc sulfate was manufactured by Merck KGaA
- silver nitrate was manufactured by Fujifilm Wako Pure Chemical Industries
- sodium chloride manufactured by Manac was manufactured by Fujifilm Wako Pure Chemical Industries
- potassium chloride manufactured by Manac calcium chloride manufactured by Fujifilm Wako Pure Chemical Industries
- magnesium chloride manufactured by Nacalai Tesque for compound (1), the above type I crystal was used.
- Test Example 8 Change in redispersibility of 0.3 w/v% compound (1)
- a suspension having the composition shown in Table 10 was prepared, and the number of times of shaking required for redispersion was determined in the same manner as in Test Example 1.
- the number of times of shaking was 15 times or less.
- the number of times of shaking was the least, 6.7 times.
- the redispersibility by inversion operation was evaluated. Good redispersibility was also confirmed by the number of operations.
- Test Example 9 Change in redispersibility due to addition of zinc chloride
- a suspension having the composition shown in Table 11 was prepared, and the number of inversion operations required for redispersion was determined in the same manner as in Test Example 5.
- High-quality eye drops can be produced by preparing aqueous suspensions having the compositions shown in Tables 12 to 14.
- the prescription amount of compound (1) and each additive is described as "g/100 mL.”
- Tyloxapol (cloud point: 90 to 100 ° C.) is manufactured by AMRI Rensselaer (Curia Global, Inc.), methyl cellulose is Metrose SM-15 manufactured by Shin-Etsu Chemical, hydroxypropylmethyl cellulose (HPMC) is 60SH-4000 manufactured by Shin-Etsu Chemical, Carboxymethyl cellulose (CMC) is Celogen PR-S manufactured by Dai-ichi Kogyo Seiyaku, and Lifitegrast is manufactured by Shanghai Sumway Pharmaceutical Technology.
- Compound (1) uses type I crystals.
- each container consists of a bottle (colorless PE, colorless PP or brown PP), a nozzle (PE) and a cap (PP).
- the appearance, brightness, chromaticity, chroma, and transmittance at each wavelength of the bottle body of each container are as specified in Table 15 and FIG.
- each container is shrink-wrapped as a product label.
- the dimensions of the bottle-shaped bottle are about 23m x about 17mm x about 50mm, and the resin weight is about 3g. Its shape is similar to the bottle of Softia (registered trademark) ophthalmic solution 0.02% (manufactured and sold by Senju Pharmaceutical Co., Ltd.).
- Bottle material polyethylene is low density polyethylene.
- Polypropylene is a propylene-ethylene copolymer having a propylene component/ethylene component ratio of 50/50 to 99.9/0.1. Senju Pharmaceutical Co., Ltd.) bottle material.
- a spectrophotometer (manufactured by Konica Minolta, Inc.) is used to measure lightness (L * value) and chromaticity (a * value, b * value). Also, the chroma (c * value) was calculated according to the formula: ((a * value) 2 +(b * value) 2 ) 1/2 .
- the transmittance (%) of light in the range of 200 to 800 nm is measured for this side portion using an ultraviolet-visible spectrophotometer ("UV-2450", manufactured by Shimadzu Corporation).
- Bottle Sterilization Method EB Eye drop bottles are sterilized by electron beam irradiation of 10 to 60 kGy.
- EOG Ethylene Oxide Gas Sterilization
- Eye drop bottles are sterilized under the conditions of ethylene oxide concentration of 400-700 mg/L, temperature of 40-50° C., relative humidity of 45-85%, and treatment time of 3 hours or longer.
- VHP Vapor Hydrogen Peroxide
- An eye drop bottle is sterilized under conditions of 3% VHP spray, temperature of 20-50° C., relative humidity of 30-90%, and treatment time of about 1 hour.
- ⁇ -ray ⁇ -ray sterilization
- Bottles are sterilized by irradiation with 20-60 kGy of ⁇ -ray.
- Method for producing 50 L scale eye drops (No. 11) Purified water and predetermined amounts of boric acid, borax, sodium chloride and zinc chloride are put into a 30 L stainless container and stirred. A predetermined amount of tyloxapol aqueous solution is prepared in a 1 L stainless container, and this aqueous solution is put into a 30 L stainless container. Furthermore, after dispersing a predetermined amount of methyl cellulose with hot water (50 to 90° C.) in another 1 L stainless steel container, it is cooled, and this methyl cellulose aqueous solution is put into a 30 L stainless steel container.
- purified water is added so as to obtain a base solution having a concentration of 1.5 times, and the weight is adjusted to a volume.
- This base solution is sterilized by filtration, and weighted up with purified water (including washing) to prepare a predetermined amount of base solution.
- Compound (1) is added to this base solution and dispersed by stirring to prepare a suspension. After confirming that the compound (1) is dispersed in the liquid, the suspension is gently stirred for defoaming. After that, the suspension is roughly filtered through a filter with a pore size of 75 ⁇ m, and the suspension is filled into a bottle while being stirred, and then the bottle is fitted with a nozzle and a cap.
- the present disclosure can be used in fields such as medicine, pharmaceuticals, healthcare, biology, and biochemistry.
Abstract
Description
(項目1)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを含む水性懸濁液剤。
(項目2)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.00007w/v%~約0.01w/v%である、上記項目に記載の水性懸濁液剤。
(項目2a)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.00007w/v%~約0.007w/v%である、上記項目に記載の水性懸濁液剤。
(項目3)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.0001w/v%~約0.008w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目3a)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.0001w/v%~約0.005w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目4)
前記セルロース系高分子がメチルセルロース、ヒドロキシプロピルメチルセルロース、およびカルボキシメチルセルロースからなる群から選択される少なくとも1種である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目5)
前記非イオン界面活性剤の前記水性懸濁液中の濃度が約0.0001w/v%~約0.5w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目6)
前記非イオン界面活性剤の前記水性懸濁液中の濃度が約0.0001w/v%~約0.1w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目6a)
前記非イオン界面活性剤の前記水性懸濁液中の濃度が約0.01w/v%~約0.05w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目7)
前記非イオン界面活性剤がチロキサポール、ポリソルベート80、モノステアリン酸ポリエチレングリコール、およびポリオキシエチレン硬化ヒマシ油からなる群から選択される少なくとも1種である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目8)
前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の前記水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目9)
さらに亜鉛塩または銀塩を含む、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目10)
前記亜鉛塩または銀塩の前記水性懸濁液中の濃度が約0.0001w/v%~約0.05w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目11)
前記亜鉛塩が塩化亜鉛または硫酸亜鉛である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目11a)
前記銀塩が硝酸銀である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目12)
前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドが、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドである、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目13)
さらにホウ酸緩衝剤を含む、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目14)
前記水性懸濁液のpHが約4~約8である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目15)
前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の再分散性が向上している、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目16)
前記再分散性の向上が、振盪操作で評価した場合に、約15回以下の振盪回数で懸濁粒子が再分散することである、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目17)
前記再分散性の向上が、転倒操作で評価した場合に、約40回以下の転倒回数で懸濁粒子が再分散することである、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目18)
前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドまたはその薬学的に許容可能な塩もしくは溶媒和物の安定性が向上している、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目19)
前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の再分散性が向上しており、かつ前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドまたはその薬学的に許容可能な塩もしくは溶媒和物の安定性が向上している、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目20)
前記水性懸濁液中の(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドまたはその薬学的に許容可能な塩もしくは溶媒和物の平均粒子径が約1μm~約5μmである、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目21)
前記水性懸濁液剤がプラスチック容器に収容されている、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目22)
前記プラスチック容器の素材がポリエチレンまたはポリプロピレンである、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目23)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを含む水性懸濁液剤であって、
該セルロース系高分子の該水性懸濁液剤中の濃度が約0.0001w/v%~約0.005w/v%であり、
該セルロース系高分子がメチルセルロース、ヒドロキシプロピルメチルセルロース、およびカルボキシメチルセルロースからなる群から選択される少なくとも1種であり、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.05w/v%であり、
該非イオン界面活性剤がチロキサポール、ポリソルベート80、およびモノステアリン酸ポリエチレングリコールからなる群から選択される少なくとも1種であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、
水性懸濁液剤。
(項目24)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを含む水性懸濁液剤であって、
該セルロース系高分子の該水性懸濁液剤中の濃度が約0.0001w/v%~約0.005w/v%であり、
該セルロース系高分子がメチルセルロース、ヒドロキシプロピルメチルセルロース、およびカルボキシメチルセルロースからなる群から選択される少なくとも1種であり、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.05w/v%であり、
該非イオン界面活性剤がチロキサポール、ポリソルベート80、およびモノステアリン酸ポリエチレングリコールからなる群から選択される少なくとも1種であり、
さらに、亜鉛塩または銀塩、およびホウ酸緩衝剤を含み、
該亜鉛塩または銀塩が塩化亜鉛、硫酸亜鉛および硝酸銀からなる群から選択される少なくとも1種であり、
該亜鉛塩または銀塩の該水性懸濁液中の濃度が約0.0005w/v%~約0.01w/v%であり、
該水性懸濁液のpHが約4~約8であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、
水性懸濁液剤。
(項目25)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを含む水性懸濁液剤であって、
該セルロース系高分子の該水性懸濁液剤中の濃度が約0.0001w/v%~約0.005w/v%であり、
該セルロース系高分子がメチルセルロースであり、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.05w/v%であり、
該非イオン界面活性剤がチロキサポールであり、
さらに、塩化亜鉛、およびホウ酸緩衝剤を含み、
該塩化亜鉛の該水性懸濁液中の濃度が約0.0005w/v%~約0.01w/v%であり、
該水性懸濁液のpHが約4~約8であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、
水性懸濁液剤。
(項目26)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを含む水性懸濁液剤であって、
該セルロース系高分子の該水性懸濁液剤中の濃度が約0.0005w/v%~約0.003w/v%であり、
該セルロース系高分子がメチルセルロースであり、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.03w/v%であり、
該非イオン界面活性剤がチロキサポールであり、
さらに、ホウ酸緩衝剤を含み、
該水性懸濁液のpHが約6.0~約8.0であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.3w/v%~約1.0w/v%であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドが、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドである、
水性懸濁液剤。
(項目27)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを含む水性懸濁液剤であって、
該セルロース系高分子の該水性懸濁液剤中の濃度が約0.0005w/v%~約0.003w/v%であり、
該セルロース系高分子がメチルセルロースであり、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.03w/v%であり、
該非イオン界面活性剤がチロキサポールであり、
さらに、塩化亜鉛、およびホウ酸緩衝剤を含み、
該塩化亜鉛の該水性懸濁液中の濃度が約0.001w/v%~約0.005w/v%であり、
該水性懸濁液のpHが約6.0~約8.0であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.3w/v%~約1.0w/v%であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドが、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドであり、
該水性懸濁液剤がプラスチック容器に収容されている、
水性懸濁液剤。
(項目A1)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、非イオン界面活性剤とを含む水性懸濁液剤。(項目B1)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、非イオン界面活性剤と、亜鉛塩または銀塩とを含む水性懸濁液剤。
(項目B2)
前記非イオン界面活性剤の前記水性懸濁液中の濃度が約0.0001w/v%~約0.5w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B2a)
前記非イオン界面活性剤の前記水性懸濁液中の濃度が約0.0001w/v%~約0.1w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B3)
前記非イオン界面活性剤の前記水性懸濁液中の濃度が約0.01w/v%~約0.05w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B4)
前記非イオン界面活性剤がチロキサポール、ポリソルベート80、モノステアリン酸ポリエチレングリコール、およびポリオキシエチレン硬化ヒマシ油からなる群から選択される少なくとも1種である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B5)
前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の前記水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B6)
前記亜鉛塩または銀塩の前記水性懸濁液中の濃度が約0.0001w/v%~約0.05w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B7)
前記亜鉛塩が塩化亜鉛または硫酸亜鉛である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B7a)
前記銀塩が硝酸銀である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B8)
さらにセルロース系高分子を含む、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B9)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.00007w/v%~約0.01w/v%である、上記項目に記載の水性懸濁液剤。
(項目B9a)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.00007w/v%~約0.007w/v%である、上記項目に記載の水性懸濁液剤。
(項目B10)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.0001w/v%~約0.008w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B10a)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.0001w/v%~約0.005w/v%である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B11)
前記セルロース系高分子がメチルセルロース、ヒドロキシプロピルメチルセルロース、およびカルボキシメチルセルロースからなる群から選択される少なくとも1種である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B12)
前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドが、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドである、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B13)
さらにホウ酸緩衝剤を含む、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B14)
前記水性懸濁液のpHが約4~約8である、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B15)
前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の再分散性が向上している、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B16)
前記再分散性の向上が、振盪操作で評価した場合に、約15回以下の振盪回数で懸濁粒子が再分散することである、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B17)
前記再分散性の向上が、転倒操作で評価した場合に、約40回以下の転倒回数で懸濁粒子が再分散することである、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B18)
前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドまたはその薬学的に許容可能な塩もしくは溶媒和物の安定性が向上している、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B19)
前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の再分散性が向上しており、かつ前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドまたはその薬学的に許容可能な塩もしくは溶媒和物の安定性が向上している、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B20)
前記水性懸濁液中の(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドまたはその薬学的に許容可能な塩もしくは溶媒和物の平均粒子径が約1μm~約5μmである、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B21)
前記水性懸濁液剤がプラスチック容器に収容されている、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B22)
前記プラスチック容器の素材がポリエチレンまたはポリプロピレンである、上記項目のいずれか一項に記載の水性懸濁液剤。
(項目B23)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、非イオン界面活性剤と、亜鉛塩または銀塩とを含む水性懸濁液剤であって、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.0001w/v%~約0.5w/v%であり、
該非イオン界面活性剤がチロキサポール、ポリソルベート80、およびモノステアリン酸ポリエチレングリコールからなる群から選択される少なくとも1種であり、
該亜鉛塩または銀塩の該水性懸濁液中の濃度が約0.0005w/v%~約0.01w/v%であり、
該亜鉛塩または銀塩が塩化亜鉛、硫酸亜鉛および硝酸銀からなる群から選択される少なくとも1種であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、
水性懸濁液剤。
(項目B24)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、非イオン界面活性剤と、亜鉛塩または銀塩とを含む水性懸濁液剤であって、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.05w/v%であり、
該非イオン界面活性剤がチロキサポール、ポリソルベート80、およびモノステアリン酸ポリエチレングリコールからなる群から選択される少なくとも1種であり、
該亜鉛塩または銀塩の該水性懸濁液中の濃度が約0.0005w/v%~約0.01w/v%であり、
該亜鉛塩または銀塩が塩化亜鉛、硫酸亜鉛および硝酸銀からなる群から選択される少なくとも1種であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、
水性懸濁液剤。
(項目B25)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、非イオン界面活性剤と、亜鉛塩とを含む水性懸濁液剤であって、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.03w/v%であり、
該非イオン界面活性剤がチロキサポールであり、
該亜鉛塩の該水性懸濁液中の濃度が約0.001w/v%~約0.005w/v%であり、
該亜鉛塩が塩化亜鉛であり、
さらに、ホウ酸緩衝剤を含み、
該水性懸濁液のpHが約6.0~約8.0であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.3w/v%~約1.0w/v%であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドが、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドであり、
該水性懸濁液剤がプラスチック容器に収容されている、
水性懸濁液剤。
(項目C1)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、チロキサポールとを含む水性懸濁液剤。
(項目D1a)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物を含む水性懸濁液剤の再分散性を向上させる方法であって、
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを混合して水性懸濁液剤を調製する工程を含む、方法。
(項目D1b)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物を含む水性懸濁液剤の再分散性を向上させる方法であって、
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物を含む水性懸濁液剤に、セルロース系高分子と、非イオン界面活性剤とを加える工程を含む、方法。
(項目D2)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.00007w/v%~約0.01w/v%である、上記項目に記載の方法。
(項目D2a)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.00007w/v%~約0.007w/v%である、上記項目に記載の方法。
(項目D3)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.0001w/v%~約0.008w/v%である、上記項目のいずれか一項に記載の方法。
(項目D3a)
前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.0001w/v%~約0.005w/v%である、上記項目のいずれか一項に記載の方法。
(項目D4)
前記セルロース系高分子がメチルセルロース、ヒドロキシプロピルメチルセルロース、およびカルボキシメチルセルロースからなる群から選択される少なくとも1種である、上記項目のいずれか一項に記載の方法。
(項目D5)
前記非イオン界面活性剤の前記水性懸濁液中の濃度が約0.0001w/v%~約0.5w/v%である、上記項目のいずれか一項に記載の方法。
(項目D6)
前記非イオン界面活性剤の前記水性懸濁液中の濃度が約0.0001w/v%~約0.1w/v%である、上記項目のいずれか一項に記載の方法。
(項目D6a)
前記非イオン界面活性剤の前記水性懸濁液中の濃度が約0.01w/v%~約0.05w/v%である、上記項目のいずれか一項に記載の方法。
(項目D7)
前記非イオン界面活性剤がチロキサポール、ポリソルベート80、モノステアリン酸ポリエチレングリコール、およびポリオキシエチレン硬化ヒマシ油からなる群から選択される少なくとも1種である、上記項目のいずれか一項に記載の方法。
(項目D8)
前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の前記水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、上記項目のいずれか一項に記載の方法。
(項目D9)
さらに亜鉛塩または銀塩を混合する工程を含む、上記項目のいずれか一項に記載の方法。
(項目D10)
前記亜鉛塩または銀塩の前記水性懸濁液中の濃度が約0.0001w/v%~約0.05w/v%である、上記項目のいずれか一項に記載の方法。
(項目D11)
前記亜鉛塩が塩化亜鉛または硫酸亜鉛である、上記項目のいずれか一項に記載の方法。
(項目D11a)
前記銀塩が硝酸銀である、上記項目のいずれか一項に記載の方法。
(項目D12)
前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドが、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドである、上記項目のいずれか一項に記載の方法。
(項目D13)
さらにホウ酸緩衝剤を混合する工程を含む、上記項目のいずれか一項に記載の方法。
(項目D14)
前記水性懸濁液のpHが約4~約8である、上記項目のいずれか一項に記載の方法。
(項目D15)
前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の再分散性が向上している、上記項目のいずれか一項に記載の方法。
(項目D16)
前記再分散性の向上が、振盪操作で評価した場合に、約15回以下の振盪回数で懸濁粒子が再分散することを含む、上記項目のいずれか一項に記載の方法。
(項目D17)
前記再分散性の向上が、転倒操作で評価した場合に、約40回以下の転倒回数で懸濁粒子が再分散することを含む、上記項目のいずれか一項に記載の方法。
(項目D18)
前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドまたはその薬学的に許容可能な塩もしくは溶媒和物の安定性が向上している、上記項目のいずれか一項に記載の方法。
(項目D19)
前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の再分散性が向上しており、かつ前記水性懸濁液中の前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドまたはその薬学的に許容可能な塩もしくは溶媒和物の安定性が向上している、上記項目のいずれか一項に記載の方法。
(項目D20)
前記水性懸濁液中の(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドまたはその薬学的に許容可能な塩もしくは溶媒和物の平均粒子径が約1μm~約5μmである、上記項目のいずれか一項に記載の方法。
(項目D21)
前記水性懸濁液剤がプラスチック容器に収容されている、上記項目のいずれか一項に記載の方法。
(項目D22)
前記プラスチック容器の素材がポリエチレンまたはポリプロピレンである、上記項目のいずれか一項に記載の方法。
(項目D23)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物を含む水性懸濁液剤の再分散性を向上させる方法であって、
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを混合して水性懸濁液剤を調製する工程を含み、
該セルロース系高分子の該水性懸濁液剤中の濃度が約0.0001w/v%~約0.005w/v%であり、
該セルロース系高分子がメチルセルロース、ヒドロキシプロピルメチルセルロース、およびカルボキシメチルセルロースからなる群から選択される少なくとも1種であり、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.05w/v%であり、
該非イオン界面活性剤がチロキサポール、ポリソルベート80、およびモノステアリン酸ポリエチレングリコールからなる群から選択される少なくとも1種であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、
方法。
(項目D24)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物を含む水性懸濁液剤の再分散性を向上させる方法であって、
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを混合して水性懸濁液剤を調製する工程を含み、
さらに、亜鉛塩または銀塩、およびホウ酸緩衝剤を配合する工程を含み、
該セルロース系高分子の該水性懸濁液剤中の濃度が約0.0001w/v%~約0.005w/v%であり、
該セルロース系高分子がメチルセルロース、ヒドロキシプロピルメチルセルロース、およびカルボキシメチルセルロースからなる群から選択される少なくとも1種であり、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.05w/v%であり、
該非イオン界面活性剤がチロキサポール、ポリソルベート80、およびモノステアリン酸ポリエチレングリコールからなる群から選択される少なくとも1種であり、
該亜鉛塩または銀塩が塩化亜鉛、硫酸亜鉛および硝酸銀からなる群から選択される少なくとも1種であり、
該亜鉛塩または銀塩の該水性懸濁液中の濃度が約0.0005w/v%~約0.01w/v%であり、
該水性懸濁液のpHが約4~約8であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、
方法。
(項目D25)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物を含む水性懸濁液剤の再分散性を向上させる方法であって、
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを混合して水性懸濁液剤を調製する工程を含み、
さらに、塩化亜鉛、およびホウ酸緩衝剤を混合する工程を含み、
該セルロース系高分子の該水性懸濁液剤中の濃度が約0.0001w/v%~約0.005w/v%であり、
該セルロース系高分子がメチルセルロースであり、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.05w/v%であり、
該非イオン界面活性剤がチロキサポールであり、
該塩化亜鉛の該水性懸濁液中の濃度が約0.0005w/v%~約0.01w/v%であり、
該水性懸濁液のpHが約4~約8であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の前記水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、
方法。
(項目D26)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物を含む水性懸濁液剤の再分散性を向上させる方法であって、
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを混合して水性懸濁液剤を調製する工程を含み、
さらに、ホウ酸緩衝剤を混合する工程を含み、
該セルロース系高分子の該水性懸濁液剤中の濃度が約0.0005w/v%~約0.003w/v%であり、
該セルロース系高分子がメチルセルロースであり、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.03w/v%であり、
該非イオン界面活性剤がチロキサポールであり、
該水性懸濁液のpHが約6.0~約8.0であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.3w/v%~約1.0w/v%であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドが、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドである、 方法。
(項目D27)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物を含む水性懸濁液剤の再分散性を向上させる方法であって、
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを混合して水性懸濁液剤を調製する工程を含み、
さらに、塩化亜鉛、およびホウ酸緩衝剤を混合する工程を含み、
該セルロース系高分子の該水性懸濁液剤中の濃度が約0.0005w/v%~約0.003w/v%であり、
該セルロース系高分子がメチルセルロースであり、
該非イオン界面活性剤の該水性懸濁液中の濃度が約0.01w/v%~約0.03w/v%であり、
該非イオン界面活性剤がチロキサポールであり、
該塩化亜鉛の該水性懸濁液中の濃度が約0.001w/v%~約0.005w/v%であり、
該水性懸濁液のpHが約6.0~約8.0であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の該水性懸濁液中の濃度が約0.3w/v%~約1.0w/v%であり、
該(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドが、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドであり、
該水性懸濁液剤がプラスチック容器に収容されている、 方法。
(項目E1)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物を含む水性懸濁液剤の再分散性を向上させる方法であって、
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、非イオン界面活性剤とを混合して水性懸濁液剤を調製する工程を含む、方法。
(項目F1)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物を含む水性懸濁液剤の再分散性を向上させる方法であって、
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、非イオン界面活性剤と、亜鉛塩または銀塩とを混合して水性懸濁液剤を調製する工程を含む、方法。
(項目G1)
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物を含む水性懸濁液剤の安定性を向上させる方法であって、
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、チロキサポールとを混合して水性懸濁液剤を調製する工程を含む、方法。
本明細書において、「約」とは、特に断らない限り、後に続く数値の±10%を意味する。
本開示において、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、非イオン界面活性剤とを含む水性懸濁液剤、が提供され得る。
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物は、水に対する溶解性が低いため、非イオン界面活性剤、イオン性界面活性剤または水溶性高分子等の分散剤の非存在下では、粒子が水面上に浮遊して、水性懸濁液の調製が不可能である。加えて、非イオン界面活性剤以外の分散剤を用いる場合には、実質的に薬学的に許容される濃度を超える濃度の分散剤を配合する必要があるため、水性懸濁液剤中には、非イオン界面活性剤の配合が不可欠である。本開示により、分散剤として非イオン界面活性剤が存在するにもかかわらず、任意の量のセルロース系高分子を配合することによって、再分散性が向上している水性懸濁液剤を提供することができる。
(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物は、水に対する溶解性が極めて低いため、本開示の水性懸濁剤では、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物は、懸濁粒子になっているが、一部は水溶液中に溶解している。本開示の一実施形態において、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物は、チロキサポールを含む水溶液に懸濁することで、水溶液中の(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の分解が抑制され、水性懸濁剤の安定性を向上させることができる。
本開示の一実施形態において、水性懸濁液剤は、眼科用懸濁液剤であり、眼注射液、点眼剤または眼灌流液として提供され得る。例えば、眼科用懸濁液剤は、水性の溶媒(例えば、リン酸緩衝生理食塩水)に有効成分を懸濁させた懸濁液の形態、或いは溶解させた液剤の形態で提供され得る。
本開示の水性懸濁液剤は、当該技術分野で公知の任意の薬学的に許容される添加物および/または賦形剤を含んでよい。添加剤としては、安定化剤、pH調節剤、緩衝剤、および保存剤(防腐剤)が挙げられるがこれらに限定されない。
本開示の水性懸濁液剤を収容する容器としては、特に限定されず、例えば、ガラス容器またはプラスチック容器等が挙げられる。プラスチック容器としては、ポリエステル(ポリエチレンテレフタレート、ポリアリレート)、ポリカーボネート、ポリエチレンまたはポリプロピレン、それらの混合物、それらとそれら以外の混合物などの任意の材料で形成され得る。本開示において用いられる容器は、医療分野で用いられるものであってもよく、それ以外であってもよい。一つの実施形態では、日本国における「点眼剤用プラスチック容器の規格」またはその他の等価の規格に合致しうる任意の材質で形成されることができる。
本明細書において用いられる分子生物学的手法、生化学的手法、微生物学的手法は、当該分野において周知であり慣用されるものであり、例えば、Sambrook J.et al.(1989).Molecular Cloning: A Laboratory Manual, Cold Spring Harborおよびその3rd Ed.(2001); Ausubel, F.M.(1987).Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Ausubel, F.M.(1989).Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Innis, M. A.(1990).PCR Protocols: A Guide to Methods and Applications, Academic Press; Ausubel, F.M.(1992).Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates; Ausubel, F.M.(1995).Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates; Innis ,M.A. et al.(1995).PCR Strategies, Academic Press; Ausubel, F.M.(1999).Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Wiley, and annual updates; Sninsky, J.J.et al.(1999).PCR Applications: Protocols for Functional Genomics, Academic Press、Gait, M.J.(1985).Oligonucleotide Synthesis: A Practical Approach, IRL Press; Gait, M.J.(1990).Oligonucleotide Synthesis: A Practical Approach, IRL Press; Eckstein, F.(1991).Oligonucleotides and Analogues: A Practical Approach, IRL Press; Adams, R.L. et al.(1992).The Biochemistry of the Nucleic Acids, Chapman & Hall; Shabarova, Z. et al.(1994).Advanced Organic Chemistry of Nucleic Acids, Weinheim; Blackburn, G.M. et al.(1996).Nucleic Acids in Chemistry and Biology, Oxford University Press; Hermanson, G.T.(I996).Bioconjugate Techniques, Academic Press、別冊実験医学「遺伝子導入&発現解析実験法」羊土社、1997等に記載されている。これらは本明細書において関連する部分(全部であり得る)が参考として援用される。
懸濁液の調製
表1に示す組成に従って、基剤溶液を調製し、化合物(1)を撹拌分散させて懸濁液を得た。チロキサポールはAMRI Rensselaer社製(Curia Global,Inc.)、メチルセルロースは信越化学工業製のものを使用した。メチルセルロースはSM-15を使用した。化合物(1)は、前記のI型結晶を使用した。
調製した懸濁液をスターラー撹拌しながら5mLずつ採取し、点眼容器に充填した。点眼容器はポリエチレンからなる無色容器(ガチフロ点眼液0.3%(製造販売元:千寿製薬株式会社)に使用されている容器)を採用した。
点眼容器に充填された懸濁液中の懸濁粒子が完全に沈降していることを確認した。振盪5回を1セットとし、点眼容器の底面および壁面から沈殿が消失するまで振盪操作を繰り返した。なお、振盪操作は上下10~15cm幅、振り下ろしてから元の位置に戻るまでを振盪1回とし、1.1秒/セットの速度で実施した。試験は1処方につき3~5検体で行い、各検体が再分散に要したセット数から平均セット数を求め、振盪回数に換算した。振盪回数が15回以下の場合を再分散良好と判断した(例:セット数1の場合は振盪回数
5回、セット数2の場合は振盪回数10回)。
沈殿が再分散するまで検体を振盪した後、レーザー回折型粒度分布測定装置(SALD-2300)の分散槽に検体を約1mL滴下した。2分間、超音波処理を行った後に粒度分布を測定し、メジアン径(D50)の値を粒子径とした。
沈殿が再分散するまで検体を振盪した後、ガラスシャーレに約10mL滴下した。シャーレを表面張力計にセットし、プレート法により表面張力を測定した。
結果を表1に示す。0.0001w/v%~0.005w/v%のメチルセルロース濃度において、振盪回数は15回以下となった。0.001w/v%メチルセルロース添加時に振盪回数が最も少なく、8.3回であった。なお、別途調製した基剤(化合物(1)およびチロキサポールを除いた処方)の表面張力は、54.6mN/mであり、再分散性と表面張力との間に相関はなかった。
表2に示す組成の懸濁液を調製し、試験例1と同様の方法で再分散に要する振盪回数を求めた。ヒドロキシプロピルメチルセルロース(HPMC)は信越化学工業製、カルボキシメチルセルロース(CMC)は第一工業製薬製のものを使用した。ヒドロキシプロピルメチルセルロースは60SH-4000、カルボキシメチルセルロースはセロゲンPR-Sを使用した。化合物(1)は、前記のI型結晶を使用した。
結果を表2に示す。0.0005w/v%~0.003w/v%のHPMCを配合することにより、振盪回数は15回以下となった。0.001w/v%のHPMCを配合したときに最も振盪回数が少なく、11.7回となった。0.001w/v%のCMCを配合することにより、振盪回数は11.7回となった。
表3に示す組成の懸濁液を調製し、試験例1と同様の方法で再分散に要する振盪回数を求めた。ポリソルベート80は日油製、モノステアリン酸ポリエチレングリコール40(MYS-40)は日本サーファクタント工業製のものを使用した。化合物(1)は、前記のI型結晶を使用した。
表4に示す組成の懸濁液を調製、試験例1と同様の方法で再分散に要する振盪回数を求めた。ポリビニルピロリドン(PVP)はBASFジャパン製、キサンタンガムはDSP五協フード&ケミカル製、カルボキシビニルポリマー(CVP)はLubrizol製のものを使用した。なお、ポリビニルピロリドンはKollidon30、カルボキシビニルポリマーは974Pを使用した。化合物(1)は、前記のI型結晶を使用した。
表5に示す組成の懸濁液を調製し、点眼容器へ充填した。塩化亜鉛はMerck KGaA製のものを使用した。化合物(1)は、前記のI型結晶を使用した。
点眼容器に充填された懸濁液中の懸濁粒子が完全に沈降していることを確認した。転倒操作を行い、点眼容器の底面および壁面から沈殿が消失し、再分散するまで繰り返した。再分散するまでに要した転倒操作数をカウントした。試験は1処方あたり3~5検体で行い、平均した転倒操作回数を算出した。
結果を表5に示す。処方28の処方にメチルセルロースを添加したところ、転倒操作回数は47.3回から24.7回になった。処方28の処方に塩化亜鉛を添加したところ、転倒操作回数は32.3回となった。メチルセルロースと塩化亜鉛を共に添加したところ、転倒操作回数は16.0回となった。
水溶液の調製
表6に示す組成に従って基剤溶液を調製し、化合物(1)を溶解して水溶液を得た。調製した水溶液を2mLずつ採取し、ガラスアンプルへ充填した。チロキサポールはRuger社製のものを使用した。化合物(1)は、前記のI型結晶を使用した。
水溶液を25℃で1ヵ月(1M)保管し、溶液中の化合物(1)含量を、以下の条件で液体クロマトグラフィー装置(島津製作所製)により測定した。含有維持率は、調製に用いた化合物(1)の量に対する保管後の測定含量の割合(%)として求めた。
・カラム:X Bridge Phenyl 3.5μm,4.6×150mm,3.5μm(Waters)
・検出器:紫外可視分光光度検出器
・検出波長:220nm
・カラム温度:40℃
・移動相:水/アセトニトリル/トリフルオロ酢酸混液(50:50:0.02)
表7~9に示す組成の懸濁液を調製し、試験例5と同様の方法で再分散に要する転倒操作回数を求めた。硫酸亜鉛はMerck KGaA製、硝酸銀は富士フィルム和光純薬製、塩化ナトリウムはマナック製、塩化カリウムはマナック製、塩化カルシウムは富士フィルム和光純薬製、塩化マグネシウムはナカライテスク製のものを使用した。化合物(1)は、前記のI型結晶を使用した。
表10に示す組成の懸濁液を調製し、試験例1と同様の方法で再分散に要する振盪回数を求めた。
表11に示す組成の懸濁液を調製し、試験例5と同様の方法で再分散に要する転倒操作回数を求めた。
表12~表14に示す組成の水性懸濁液剤を調製することで、高品質の点眼剤を製造することができる。なお、化合物(1)および各添加剤の処方量は「g/100mL」として表記する。
各容器は、ボトル(無色PE、無色PPまたは褐色PP)、ノズル(PE)、およびキャップ(PP)で構成されている。各容器のボトルの胴部の外観、明度、色度、彩度、および各波長における透過率は、表15および図1に示す仕様のとおりである。また、各容器は製品ラベルとしてシュリンク包装されている。
ボトルの寸法は、約23m×約17mm×約50mmであり、樹脂重量は約3gである。その形状は、ソフティア(登録商標)点眼液0.02%(製造販売元:千寿製薬株式会社)のボトルと同様である。
ポリエチレンは、低密度ポリエチレンである。ポリプロピレンは、プロピレン成分/エチレン成分=50/50~99.9/0.1として構成されているプロピレン-エチレン共重合体であり、ソフティア(登録商標)点眼液0.02%(製造販売元:千寿製薬株式会社)のボトル材質と同様である。
ボトルの胴部から切り取った側面部(広い方の側面部,1.0cm×2.0~3.0cm)について、分光測色計(CM-5、コニカミノルタ株式会社製)を用いて、明度(L*値)および色度(a*値、b*値)を測定する。また、式:((a*値)2+(b*値)2)1/2に従って、彩度(c*値)を算出した。また、この側面部について、紫外可視分光光度計(「UV-2450型」、株式会社島津製作所製)を用いて、200~800nmの領域の光の透過率(%)を測定する。
EB(電子線照射滅菌):点眼ボトルは電子線を10~60kGy照射により滅菌処理される。
EOG(エチレンオキサイドガス滅菌):点眼ボトルはエチレンオキサイド濃度400~700mg/L、温度40~50℃、相対湿度45~85%、処理時間3時間以上の条件で滅菌処理される。
VHP(過酸化水素ガス滅菌:Vaporous Hydrogen Peroxide):点眼ボトルは、3%VHP噴霧、温度20~50℃、相対湿度30~90%、処理時間約1時間の条件で滅菌処理される。
γ線(γ線滅菌):ボトルはγ線を20~60kGy照射により滅菌処理される。
30Lステンレス容器に精製水と所定量のホウ酸、ホウ砂、塩化ナトリウムおよび塩化亜鉛を投入して撹拌する。1Lステンレス容器で所定量のチロキサポール水溶液を調製し、この水溶液を30Lステンレス容器に投入する。さらに別の1Lステンレス容器にて所定量のメチルセルロースを熱水で分散(50~90℃)した後、冷却し、このメチルセルロース水溶液を30Lステンレス容器に投入する。30Lステンレス容器において、すべての添加剤が溶解したことを確認し、1.5倍濃度の基剤溶液となるように精製水を投入して重量メスアップを行う。この基剤溶液をろ過滅菌し、精製水(洗い込みを含む)で重量メスアップを行い、所定量の基剤溶液を調製する。この基材溶液に化合物(1)を投入し、撹拌により分散させて、懸濁液を調製する。化合物(1)の液中分散を確認後、消泡のために懸濁液をゆるやかに撹拌する。その後、懸濁液を孔径75μmのフィルターにて粗ろ過を行い、懸濁液を撹拌しながらボトルに充填し、その後、ボトルにノズルとキャップを装着する。
以上のように、本開示の好ましい実施形態を用いて本開示を例示してきたが、本開示は、特許請求の範囲によってのみその範囲が解釈されるべきであることが理解される。本明細書において引用した特許、特許出願および他の文献は、その内容自体が具体的に本明細書に記載されているのと同様にその内容が本明細書に対する参考として援用されるべきであることが理解される。本願は、日本国特許庁に2021年3月30日に出願された特願2021-57713に対して優先権主張をするものであり、その内容はその全体があたかも本願の内容を構成するのと同様に参考として援用される。
Claims (13)
- (E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物と、セルロース系高分子と、非イオン界面活性剤とを含む水性懸濁液剤。
- 前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.00007w/v%~約0.01w/v%である、請求項1に記載の水性懸濁液剤。
- 前記セルロース系高分子の前記水性懸濁液剤中の濃度が約0.0001w/v%~約0.008w/v%である、請求項1または2に記載の水性懸濁液剤。
- 前記セルロース系高分子がメチルセルロース、ヒドロキシプロピルメチルセルロース、およびカルボキシメチルセルロースからなる群から選択される少なくとも1種である、請求項1~3のいずれか一項に記載の水性懸濁液剤。
- 前記非イオン界面活性剤の前記水性懸濁液中の濃度が約0.0001w/v%~約0.5w/v%である、請求項1~4のいずれか一項に記載の水性懸濁液剤。
- 前記非イオン界面活性剤の前記水性懸濁液中の濃度が約0.0001w/v%~約0.1w/v%である、請求項1~5のいずれか一項に記載の水性懸濁液剤。
- 前記非イオン界面活性剤がチロキサポール、ポリソルベート80、モノステアリン酸ポリエチレングリコール、およびポリオキシエチレン硬化ヒマシ油からなる群から選択される少なくとも1種である、請求項1~6のいずれか一項に記載の水性懸濁液剤。
- 前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミド、またはその薬学的に許容可能な塩もしくは溶媒和物の前記水性懸濁液中の濃度が約0.01w/v%~約5w/v%である、請求項1~7のいずれか一項に記載の水性懸濁液剤。
- さらに亜鉛塩または銀塩を含む、請求項1~8のいずれか一項に記載の水性懸濁液剤。
- 前記亜鉛塩または銀塩の前記水性懸濁液中の濃度が約0.0001w/v%~約0.05w/v%である、請求項9に記載の水性懸濁液剤。
- 前記亜鉛塩が塩化亜鉛または硫酸亜鉛である、請求項9または10に記載の水性懸濁液剤。
- 前記銀塩が硝酸銀である、請求項9または10に記載の水性懸濁液剤。
- 前記(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-(7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドが、(E)-2-(7-トリフルオロメチルクロマン-4-イリデン)-N-((7R)-7-ヒドロキシ-5,6,7,8-テトラヒドロナフタレン-1-イル)アセトアミドである、請求項1~12のいずれか一項に記載の水性懸濁液剤。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022546133A JP7175431B1 (ja) | 2021-03-30 | 2022-03-29 | ヘテロシクリデンアセトアミド誘導体含有懸濁液 |
CN202280026310.3A CN117120048A (zh) | 2021-03-30 | 2022-03-29 | 含杂环亚基乙酰胺衍生物的悬浮液 |
BR112023019820A BR112023019820A2 (pt) | 2021-03-30 | 2022-03-29 | Suspensão contendo derivado de heterociclidenoacetamida |
AU2022250028A AU2022250028A1 (en) | 2021-03-30 | 2022-03-29 | Suspension containing heterocyclidene acetamide derivative |
CA3215750A CA3215750A1 (en) | 2021-03-30 | 2022-03-29 | Suspension containing heterocyclidene acetamide derivative |
KR1020237037161A KR20230163502A (ko) | 2021-03-30 | 2022-03-29 | 헤테로시클리덴 아세트아미드 유도체 함유 현탁액 |
EP22780995.1A EP4316485A1 (en) | 2021-03-30 | 2022-03-29 | Suspension containing heterocyclidene acetamide derivative |
JP2022178888A JP7273235B2 (ja) | 2021-03-30 | 2022-11-08 | ヘテロシクリデンアセトアミド誘導体含有懸濁液 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-057713 | 2021-03-30 | ||
JP2021057713 | 2021-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022210784A1 true WO2022210784A1 (ja) | 2022-10-06 |
Family
ID=83459508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/015691 WO2022210784A1 (ja) | 2021-03-30 | 2022-03-29 | ヘテロシクリデンアセトアミド誘導体含有懸濁液 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4316485A1 (ja) |
JP (3) | JP7175431B1 (ja) |
KR (1) | KR20230163502A (ja) |
CN (1) | CN117120048A (ja) |
AU (1) | AU2022250028A1 (ja) |
BR (1) | BR112023019820A2 (ja) |
CA (1) | CA3215750A1 (ja) |
WO (1) | WO2022210784A1 (ja) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0530569B2 (ja) | 1985-01-11 | 1993-05-10 | Inoue Japax Res | |
JPH07304663A (ja) * | 1994-03-18 | 1995-11-21 | Senju Pharmaceut Co Ltd | 眼圧降下用点眼剤 |
JPH1129463A (ja) * | 1997-05-14 | 1999-02-02 | Senju Pharmaceut Co Ltd | 再分散性の良い水性懸濁液剤 |
WO2007010383A1 (ja) | 2005-07-22 | 2007-01-25 | Mochida Pharmaceutical Co., Ltd. | 新規なヘテロシクリデンアセトアミド誘導体 |
JP6230743B1 (ja) | 2017-05-31 | 2017-11-15 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の結晶 |
WO2021039023A1 (ja) | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
WO2021039748A1 (ja) * | 2019-08-27 | 2021-03-04 | 参天製薬株式会社 | ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物 |
WO2021038889A1 (ja) | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
JP2021057713A (ja) | 2019-09-27 | 2021-04-08 | ブラザー工業株式会社 | 通信装置と通信装置のためのコンピュータプログラム |
WO2021066144A1 (ja) * | 2019-10-04 | 2021-04-08 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有医薬 |
-
2022
- 2022-03-29 EP EP22780995.1A patent/EP4316485A1/en active Pending
- 2022-03-29 AU AU2022250028A patent/AU2022250028A1/en active Pending
- 2022-03-29 WO PCT/JP2022/015691 patent/WO2022210784A1/ja active Application Filing
- 2022-03-29 BR BR112023019820A patent/BR112023019820A2/pt unknown
- 2022-03-29 CA CA3215750A patent/CA3215750A1/en active Pending
- 2022-03-29 KR KR1020237037161A patent/KR20230163502A/ko unknown
- 2022-03-29 JP JP2022546133A patent/JP7175431B1/ja active Active
- 2022-03-29 CN CN202280026310.3A patent/CN117120048A/zh active Pending
- 2022-11-08 JP JP2022178888A patent/JP7273235B2/ja active Active
-
2023
- 2023-04-27 JP JP2023073689A patent/JP2023099107A/ja active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0530569B2 (ja) | 1985-01-11 | 1993-05-10 | Inoue Japax Res | |
JPH07304663A (ja) * | 1994-03-18 | 1995-11-21 | Senju Pharmaceut Co Ltd | 眼圧降下用点眼剤 |
JPH1129463A (ja) * | 1997-05-14 | 1999-02-02 | Senju Pharmaceut Co Ltd | 再分散性の良い水性懸濁液剤 |
WO2007010383A1 (ja) | 2005-07-22 | 2007-01-25 | Mochida Pharmaceutical Co., Ltd. | 新規なヘテロシクリデンアセトアミド誘導体 |
JP4754566B2 (ja) | 2005-07-22 | 2011-08-24 | 持田製薬株式会社 | 新規なヘテロシクリデンアセトアミド誘導体 |
JP6230743B1 (ja) | 2017-05-31 | 2017-11-15 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の結晶 |
WO2018221543A1 (ja) | 2017-05-31 | 2018-12-06 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の結晶 |
WO2021039023A1 (ja) | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
WO2021038889A1 (ja) | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
WO2021039748A1 (ja) * | 2019-08-27 | 2021-03-04 | 参天製薬株式会社 | ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物 |
JP2021057713A (ja) | 2019-09-27 | 2021-04-08 | ブラザー工業株式会社 | 通信装置と通信装置のためのコンピュータプログラム |
WO2021066144A1 (ja) * | 2019-10-04 | 2021-04-08 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有医薬 |
Non-Patent Citations (11)
Title |
---|
AUSUBEL, F.M.: "Current Protocols in Molecular Biology", 1987, GREENE PUB. ASSOCIATES AND WILEY-INTERSCIENCE |
BESSATSU JIKKEN IGAKU: "Gene transfer expression analysis experimental method", 1997, YODOSHA CO., LTD. |
BIOCHEMISTRY, vol. 85,7, pages 561 - 565 |
ECKSTEIN, F.: "Oligonucleotides and Analogues: A Practical Approach", 1991, IRL PRESS |
GAIT, M.J.: "Oligonucleotide Synthesis: A Practical Approach", 1985, IRL PRESS |
HERMANSON, G.T.: "Nucleic Acids in Chemistry and Biology", 1996, OXFORD UNIVERSITY PRESS |
INNIS, M. A.: "PCR Protocols: A Guide to Methods and Applications", 1990, ACADEMIC PRESS |
NAGAI NORIAKI: "Evaluation Based on Pharmaceutical Characteristics and Design of Novel Nanomedicine in the Ophthalmic Field", IRYO YAKUGAKU - JAPANESE JOURNAL OF PHARMACEUTICAL HEALTH CAREAND SCIENCES, NIHON BYOIN YAKUZAISHIKAI, TOKYO, JP, vol. 44, no. 10, 10 October 2018 (2018-10-10), JP , pages 481 - 490, XP055932154, ISSN: 1346-342X, DOI: 10.5649/jjphcs.44.481 * |
SEIKAGAKU, THE JOURNAL OF JAPANESE BIOCHEMICAL SOCIETY, vol. 85, no. 7, pages 561 - 565 |
SHABAROVA, Z. ET AL., ADVANCED ORGANIC CHEMISTRY OF NUCLEIC ACIDS, WEINHEIM, 1994 |
SNINSKY, J.J. ET AL.: "Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology", 1999, GREENE PUB. ASSOCIATES AND WILEY-INTERSCIENCE |
Also Published As
Publication number | Publication date |
---|---|
JP2023011898A (ja) | 2023-01-24 |
JP7273235B2 (ja) | 2023-05-12 |
AU2022250028A1 (en) | 2023-11-16 |
KR20230163502A (ko) | 2023-11-30 |
JP2023099107A (ja) | 2023-07-11 |
JPWO2022210784A1 (ja) | 2022-10-06 |
CA3215750A1 (en) | 2022-10-06 |
CN117120048A (zh) | 2023-11-24 |
BR112023019820A2 (pt) | 2023-11-07 |
JP7175431B1 (ja) | 2022-11-18 |
EP4316485A1 (en) | 2024-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3612228B1 (en) | Iodine compositions | |
JP5661640B2 (ja) | 薬学的懸濁物 | |
JP6701412B2 (ja) | 水溶性高分子を含む水性液剤 | |
KR20090093581A (ko) | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 | |
JP2012511009A5 (ja) | ||
TWI745358B (zh) | 含有細微粒子之組合物及其製法 | |
KR20160048189A (ko) | 점안제 | |
TW201733578A (zh) | 含多佐胺與溴莫尼定之醫藥組成物 | |
JP7175431B1 (ja) | ヘテロシクリデンアセトアミド誘導体含有懸濁液 | |
KR20100014632A (ko) | 플루오로메토론을 함유하는 현탁형 점안제 | |
JPWO2012099142A1 (ja) | 保存効力を有するブロムフェナク水性液剤組成物 | |
JP6177594B2 (ja) | 水性眼科組成物 | |
WO2024071349A1 (ja) | ヘテロシクリデンアセトアミド誘導体を含む配合剤 | |
JP2010265261A (ja) | レボカバスチン懸濁型点眼剤 | |
WO2024071348A1 (ja) | 滅菌処理したヘテロシクリデンアセトアミド誘導体含有懸濁液 | |
JP2007016024A (ja) | ロフルミラスト点眼液 | |
WO2018215638A1 (en) | Pharmaceutical compositions comprising azithromycin | |
US11179294B2 (en) | Preservative removal from eye drops | |
JP6730500B2 (ja) | 水性液剤 | |
JP7197726B2 (ja) | ソフトコンタクトレンズ用医薬組成物 | |
JP2023509400A (ja) | 微粒子を含有する医薬組成物の製造方法 | |
WO2020085190A1 (ja) | 水性眼科用組成物及び保存効力向上方法 | |
TW202404603A (zh) | 包含cftr活化劑的組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2022546133 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22780995 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2301006324 Country of ref document: TH |
|
ENP | Entry into the national phase |
Ref document number: 3215750 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/011649 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023019820 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20237037161 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022250028 Country of ref document: AU Ref document number: AU2022250028 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023127623 Country of ref document: RU Ref document number: 2022780995 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022780995 Country of ref document: EP Effective date: 20231030 |
|
ENP | Entry into the national phase |
Ref document number: 112023019820 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230926 |
|
ENP | Entry into the national phase |
Ref document number: 2022250028 Country of ref document: AU Date of ref document: 20220329 Kind code of ref document: A |